HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cholestin Red Yeast Rice Shipments Halted Pending FDA Talks

This article was originally published in The Tan Sheet

Executive Summary

Pharmanex suspended U.S. shipments of Cholestin April 2 following a federal court decision affirming FDA's determination that the red yeast rice product is a drug, not a dietary supplement.

You may also be interested in...



Questions Circle INDs; Industry Needs Guidance For Probiotics, Say Experts

FDA should consider issuing a guidance for probiotics similar to the 2004 industry guidance for botanical drugs, panelists said at a recent Drug Information Association conference

Linnea

New Melilotus (yellow sweet clover) extract for "venous system" support contains coumarin, "the active ingredient in blood-thinning prescription drugs such as Coumadin," according to Swiss-based extract supplier. Linnea, which is introducing the extract to U.S. supplement market, says it has not spoken with FDA regarding whether agency might consider ingredient a "new drug." Cholestin maker Pharmanex removed red yeast rice from its products following court ruling affirming FDA's determination it contains the same active ingredient as Merck's cholesterol-lowering drug Mevacor (1"The Tan Sheet" April 9, p. 3)...

Red Yeast Rice Enforcement Actions, Product Withdrawals Underway

FDA is stepping up enforcement activity against red yeast rice product manufacturers and marketers in the wake of a Utah federal judge's recent decision finding the ingredient to be a drug, not a dietary supplement.

Related Content

Topics

UsernamePublicRestriction

Register

RS132257

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel